Back to Results

Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients

Interested in this Trial?

Contact Us

Trial Status Completed

Trial Identifier

NCT01114737

Condition

Phenylketonuria

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

This double-blind, placebo-controlled, randomized study is designed to evaluate the safety and therapeutic effects of sapropterin dihydrochloride on neuropsychiatric symptoms in subjects with PKU.

Eligibility Criteria

Birth Sex

All

Age

8 Years to 65 Years

Healthy Volunteers

No

Drug/Treatment:

Sapropterin dihydrochloride, Placebo

Phase:

Phase 3

Study Type:

Interventional

Number of Participants:

206

Study Started:

2010-08

Study Updated:

2016-02-01

Trial Locations

  • La Jolla, California, United States

  • Los Angeles, California, United States

  • Palo Alto, California, United States

  • San Francisco, California, United States

  • Aurora, Colorado, United States

  • Washington DC, District of Columbia, United States

  • Gainesville, Florida, United States

  • Tampa, Florida, United States

  • Atlanta, Georgia, United States

  • Chicago, Illinois, United States

  • Indianapolis, Indiana, United States

  • Boston, Massachusetts, United States

  • Minneapolis, Minnesota, United States

  • Albany, New York, United States

  • Buffalo, New York, United States

  • Rochester, New York, United States

  • Chapel Hill, North Carolina, United States

  • Cleveland, Ohio, United States

  • Portland, Oregon, United States

  • Hershey, Pennsylvania, United States

  • Philadelphia, Pennsylvania, United States

  • Pittsburgh, Pennsylvania, United States

  • Nashville, Tennessee, United States

  • Dallas, Texas, United States

  • Madison, Wisconsin, United States

  • Milwaukee, Wisconsin, United States

  • Calgary, Alberta, Canada

  • Edmonton, Alberta, Canada

  • Vancouver, British Columbia, Canada

  • Winnipeg, Manitoba, Canada

  • Halifax, Nova Scotia, Canada

  • Hamilton, Ontario, Canada

  • Kingston, Ontario, Canada

  • London, Ontario, Canada

  • Toronto, Ontario, Canada

  • Montreal, Quebec, Canada

Inclusion Criteria

  • ≥ 8 years of age
  • Confirmed diagnosis of PKU
  • Willing to continue current diet (typical diet for the 3 months prior to study entry) unchanged while participating in the study
  • Willing and able to provide written, signed informed consent or in the case of subjects under the age of 18, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures
  • Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study and for at least 30 days following the last dose of sapropterin dihydrochloride
  • Females of childbearing potential must have a negative pregnancy test at screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to screening, or have had total hysterectomy.
  • Willing and able to comply with all study procedure

Exclusion Criteria

  • Has known hypersensitivity to sapropterin dihydrochloride or its excipients
  • Subject breastfeeding at screening or planning to become pregnant (subject or partner) at any time during the study
  • Use of any investigational product or investigational medical device within 30 days prior to screening, or requirement for any investigational agent prior to the completion of all scheduled study assessments
  • Received sapropterin dihydrochloride within 16 weeks of randomization
  • Have initiated or adjusted medication for treatment of ADHD, depression, or anxiety ≤ 8 weeks prior to randomization
  • Taking medication known to inhibit folate synthesis (eg, methotrexate)
  • Any condition requiring treatment with levodopa or any PDE-5 inhibitor
  • Concurrent disease or condition that would interfere with study participation, compliance or safety as determined by the Investigator
  • Any condition that, in the view of the Investigator, places the subject at high risk of poor treatment compliance or of not completing the stud

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our active clinical trials

*required fields

"*" indicates required fields

Please select the trial that you are interested in from the dropdown below. Note that this list only includes currently active trials. If you cannot find the trial you are seeking, please enter the study identifier and title in the comments box below, along with any other details you would like us to know to help address your inquiry.
Consent*
Consent*
For more Information about BioMarin's privacy obligations or to exercise your privacy rights, please visit BioMarin's Data Privacy Center.
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form

What’s Next?

Visit the following links to learn more about clinical trials.

Discuss this trial with your care team.

You may wish to print this page to share the details with your healthcare providers and discuss whether you may be eligible.

Print

Get in touch.

Contact Us